Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PMN-310 by ProMIS Neurosciences for Alzheimer's Disease: Likelihood of Approval
PMN-310 is under clinical development by ProMIS Neurosciences and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...